ESC 365 - Safety and tolerability of a first in class chymase inhibitor in clinically stable patients with left-ventricular dysfunction after myocardial infarction

HFA Premium Access

Safety and tolerability of a first in class chymase inhibitor in clinically stable patients with left-ventricular dysfunction after myocardial infarction

Session: Poster Session 4 - Chronic Heart Failure – Pathophysiology and Mechanisms

Topic: Pathophysiology and Mechanisms

Speaker: Doctor M. Senni (Bergamo, IT)

Event: Heart Failure 2018

Congress Presentation

Add to my library

About the speaker

Doctor Michele Senni

Papa Giovanni XXIII Hospital, Bergamo (Italy)

49 presentations

2 followers

25 more presentations in this session

The relations between pro- and anti-inflammatory cytokines contractile ability of the myocardium in patients with coronary artery disease

Predictors of galectin-3 in patients with heart failure and reduced ejection fraction

Speaker: Doctor I. Alexanian (Athens, GR)

The role of Response-to-Diuretic in predicting prognosis in discharged heart failure patients after an acute decompensation.

Speaker: Doctor M. Feola (Mondovi, IT)

Mobile cardiopaging in toxic cardiomyopathy diagnostics in cancer patients

Speaker: Professor N. Lyamina (Moscow, RU)

Use of sacubitril valsartan in heart failure due to post-chemotherapy symptomatic ventricular dysfunction

Speaker: Doctor V. Gregorietti (Buenos Aires, AR)

Access the full session

Poster Session 4 - Chronic Heart Failure – Pathophysiology and Mechanisms

Speakers: Doctor M. Senni, Doctor I. Alexanian, Doctor M. Feola, Professor N. Lyamina, Doctor V. Gregorietti

About the event

Heart Failure 2018

26 May - 29 May 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources